Malvern Instruments Ltd.
Malvern Instruments Ltd.
Malvern Instruments Ltd and Paraytec | Date: 2017-08-30
A method (101) of determining a diffusion coefficient (D) or hydrodynamic radius of a solute in a solution flowing in a capillary is disclosed, comprising: obtaining a first Taylorgram (501) comprising a plurality of measurements of solute concentration measured at a first residence time; obtaining a second Taylorgram (502) comprising a plurality of measurements of solute concentration measured at a second residence time; determining a first front amplitude A of a solute front from the first Taylorgram (501); determining a second front amplitude A of a solute front from the second Taylorgram (502); calculating an actual front height ratio A/A of the second front amplitude A to the first front amplitude A; and deriving a value of the diffusion coefficient (D) or hydrodynamic radius of the solute from the actual front height ratio A/A.
Malvern Instruments Ltd | Date: 2017-01-11
A method of determining a relationship between a mutual diffusion co-efficient D_(m) and the concentration c of a solute within a solvent. The method comprises: obtaining a Taylorgram (100) comprising a plurality of measurements of solute concentration c; and deriving from the Taylorgram (200) a plurality of mutual diffusion coefficient values D_(m) corresponding with a plurality of different concentrations c of solute in the solvent.
Malvern Instruments Ltd | Date: 2016-12-28
The invention relates to methods and apparatus for detecting properties of heterogeneous samples, including detecting properties of particles or fluid droplets in industrial processes. Embodiments disclosed include a particle characterization method, comprising: providing a fluid containing suspended particles; causing at least a first subset of the suspended particles to flow past a first two-dimensional array detector (24); illuminating the first subset of suspended particles as they flow past the first two-dimensional array detector (24) in the fluid; acquiring a plurality of images of the first subset of particles as they flow past the first two-dimensional array detector (24) in the fluid; and automatically counting the particles in the images.
Malvern Instruments Ltd | Date: 2017-07-12
A particle characterisation apparatus (300) is disclosed comprising: a sample cell (110) for holding a sample (150), a light source (302) for producing a light beam (106) for illuminating the sample (150) in the sample cell (110), thereby producing scattered light by the interaction of the light beam (106) with the sample (150); a focussing lens (130) for focussing the light beam (106) within the sample (150); and a detector (306) for detecting the backscattered light along a detection optical path (108) that intersects the focussed light beam (106) within the sample (150). The intersection of the light beam (106) and the detection optical path (108) in the sample define a detection region (120). The apparatus comprises an optical arrangement for varying the volume of the detection region (120).
Malvern Instruments Ltd | Date: 2017-03-01
A particle characterization apparatus and corresponding method is disclosed. The apparatus comprises a sample cell (14). The sample cell includes: an input opening (26) for receiving a fluid that carries particles flowing along a flow axis, a central acquisition channel (32) hydraulically responsive to the input opening (26) for receiving a first subset of the fluid,a pair of lateral bypass channels (32, 34) hydraulically responsive to the input opening (26) and disposed on either side of the central acquisition channel (32) for receiving second and third subsets of the fluid,a window (36) in the central acquisition channel (32) for illuminating the first subset of the fluid in the central acquisition channel (32),an illumination source (18) positioned to illuminate the fluid in the central acquisition channel (32) through the window (36), and a detector (20) positioned to receive light from the fluid in the central acquisition channel (32) after it has interacted with the fluid.
Malvern Instruments Ltd | Date: 2017-02-01
A method of Raman spectroscopic structure investigation of a sample that includes a dispersed chemical species, in particular a protein, in a liquid phase and an apparatus for performing said method are described. The method comprises: providing the sample; providing marker particles in the sample; exciting the sample with a light source; receiving Raman-scattered light from the dispersed chemical species in the sample; detecting, from the received Raman-scattered light, Raman scattering from the dispersed chemical species in the sample; detecting movement of the marker particles in the sample; and extracting at least one characteristic of the dispersed chemical species in the sample from both the step of detecting Raman scattering and the step of detecting movement of the particles.
Malvern Instruments Ltd | Date: 2017-09-20
An apparatus (200) for particle characterisation, comprising: a sample cell (210) for holding a sample (215); a light source (220) configured to illuminate the sample (215) with an illuminating beam (230) and a plurality of light detectors (240, 241, 242), each light detector (240, 241, 242) configured to receive scattered light resulting from the interaction between the illuminating beam (230) and the sample (215) along a respective detector path (250, 251, 252), wherein each respective detector path (250, 251, 252) is at substantially the same angle (260) to the illuminating beam (230).
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: NMP-28-2014 | Award Amount: 11.30M | Year: 2015
Concept: NanoFASE will deliver an integrated Exposure Assessment Framework, including methods, parameter values, model and guidance that will allow Industry to assess the full diversity of industrial nano-enabled products to a standard acceptable in regulatory registrations. Methods to assess how use phases, waste streams and environmental compartments (air, soil, water biota) act as reactors in modifying and transporting ENMs will be developed and used to derive parameter values. Our nanospecific models will be integrated with the existing multi-media fate model SimpleBox4Nano for use in EUSES and also develop into a flexible multi-media model for risk assessment at different scales and complexities. Information on release form, transformation and transport processes for product relevant ENMs will allow grouping into Functional Fate Groups according to their most probable fate pathways as a contribution to safe-by-design based on fate. Methodology: Inventories of material release forms along the product value chain are established. We then study how released ENMs transform from initial reactive states to modified forms with lower energy states in which nanospecific properties may be lost. Transport studies assess material fluxes within/between compartments. The experimental work underpins models describing ENM transformation and transport. Open access is provided to the models suitable for incorporation into existing exposure assessment tools (e.g. SimpleBox4Nano) and for more detailed assessment. Framework completeness is validated by case studies. Impact: Identified links between ENM material properties and fate outcome (e.g. safe-by-design). Improved representation of nanospecific processes in existing key fate and exposure assessment tools (e.g. SimpleBox4Nano in EUSES). Contribution to standardization. GIS framework to support predictive assessment, catchment and point source management of ENM releases.
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: NMBP-26-2016 | Award Amount: 10.76M | Year: 2016
An increasing number of nanomaterials (NMs) are entering the market in every day products spanning from health care and leisure to electronics, cosmetics and foodstuff. Nanotechnology is a truly enabling technology, with unlimited potential for innovation. However, the novelty in properties and forms of NMs makes the development of a well-founded and robust legislative framework to ensure safe development of nano-enabled products particularly challenging. At the heart of the challenge lies the difficulty in the reliable and reproducible characterisation of NMs given their extreme diversity and dynamic nature, particularly in complex environments, such as within different biological, environmental and technological compartments. Two key steps can resolve this: 1) the development of a holistic framework for reproducible NM characterisation, spanning from initial needs assessment through method selection to data interpretation and storage; and 2) the embedding of this framework in an operational, linked-up ontological regime to allow identification of causal relationships between NMs properties, be they intrinsic, extrinsic or calculated, and biological, (eco)toxicological and health impacts fully embedded in a mechanistic risk assessment framework. ACEnano was conceived in response to the NMBP 26 call with the aim to comprehensively address these two steps. More specifically ACEnano will introduce confidence, adaptability and clarity into NM risk assessment by developing a widely implementable and robust tiered approach to NM physico-chemical characterisation that will simplify and facilitate contextual (hazard or exposure) description and its transcription into a reliable NMs grouping framework. This will be achieved by the creation of a conceptual toolbox that will facilitate decision-making in choice of techniques and SOPs, linked to a characterisation ontology framework for grouping and risk assessment and a supporting data management system.
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: NMBP-10-2016 | Award Amount: 6.00M | Year: 2017
The overall objective of B-SMART is: 1. to design modular nanoparticles, 2. to manufacture them via a quality-by-design protocol, 3. to achieve delivery of therapeutic RNAs to the brain and treat neurodegenerative diseases. I. To design modular nanoparticles consisting of o an active RNA payload o established (lipid-based), emerging (trigger-responsive polymer-based) or exploratory (extracellular vesicle-based) nanoparticles o a targeting ligand consisting of the variable domain of heavy chain only antibodies (also known as VHHs or nanobodies), which are coupled to the carrier platform II. To manufacture the modular nanoparticles using a microfluidic assembly system that will ensure quality-by-design: uniform nanoparticles across research sites and excellent control over the physico-chemical parameters. III. To test pre-clinical activity of formulations with promising in vitro activity with good cell/blood compatibility and to select the best RNA-formulation for clinical translation to treat neurodegenerative diseases. Pre-clinical efficacy is tested after o local injection o nasal administration o systemic administration The neurodegenerative diseases carry a high burden for patients since they are without exception progressive. But they also carry a substantial socio-economic burden with estimated costs of 130 billion euro. per year (2008). IV. The technical work in B-SMART will be supported by project management. It ensures that the project is coordinated in a clear, unambiguous and mutually acceptable manner and that the project achieves its objectives, within the given financial and time constraints. in B-SMART we expect to arrive at a scale-able nanoparticle formulation with uniform characteristics that shows strong pre-clinical evidence of therapeutic efficacy and is ready for clinical translation.